GROWTH OF CHILDREN WITH HYPOCHONDROPLASIA TREATED WITH GROWTH-HORMONE FOR UP TO 3 YEARS
GROWTH OF CHILDREN WITH HYPOCHONDROPLASIA TREATED WITH GROWTH-HORMONE FOR UP TO 3 YEARS
复制标题
DOI：
10.1159/000182190
复制
发表时间：
1991-01-01
期刊：
影响因子：
--
通讯作者：
BROOK, CGD
中科院分区：
文献类型：
--
作者：
BRIDGES, NA;HINDMARSH, PC;BROOK, CGD
软骨发育不良是一种骨骼发育不良，其特征是儿童期生长不良和青春期生长不足。31名放射学诊断为软骨发育不全的儿童接受了长达3年的重组人生长激素治疗，平均剂量为17.9 U/m2/周，每日皮下注射。平均治疗前身高增速标准差评分（SDS）为-0.51;治疗1年后增加至+1.58。这种改善在未来两年会减少。对最终身高的影响尚不清楚。治疗组内的临床反应存在相当大的差异。
Hypochondroplasia is a skeletal dysplasia characterised by poor childhood growth and an inadequate pubertal growth spurt. 31 children with a radiological diagnosis of hypochondroplasia have been treated for up to 3 years with recombinant human growth hormone, mean dose 17.9 U/m2/week as daily subcutaneous injections. Mean pre-treatment height velocity standard deviation score (SDS) was -0.51; this increased to +1.58 after 1 year of treatment. This improvement diminishes over the next 2 years. The effect on final height remains unknown. There was a considerable variation in clinical response within the group treated.